Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system
{{output}}
Background: In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CPMS), yet... ...
